Prestige BioPharma Limited (950210.KS)
KRW 15050.0
(-4.57%)
KRW 15050.0
(-4.57%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -62.78 Billion KRW | 9.76% |
| 2022 | -69.57 Billion KRW | -18.89% |
| 2021 | -58.51 Billion KRW | -218.3% |
| 2020 | -18.38 Billion KRW | -69.08% |
| 2019 | -10.87 Billion KRW | -146.89% |
| 2018 | -4.4 Billion KRW | -36.13% |
| 2017 | -3.23 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q2 | -19.02 Billion KRW | -10.76% |
| 2023 Q3 | -16.85 Billion KRW | 11.38% |
| 2023 Q4 | -9.74 Billion KRW | 42.2% |
| 2023 Q1 | -17.17 Billion KRW | 17.76% |
| 2022 Q1 | -12.35 Billion KRW | 60.45% |
| 2022 Q4 | -20.88 Billion KRW | -5.88% |
| 2022 FY | -69.57 Billion KRW | -18.89% |
| 2022 Q2 | -17.03 Billion KRW | -37.8% |
| 2022 Q3 | -19.72 Billion KRW | -15.83% |
| 2021 Q1 | -5.3 Billion KRW | -33.62% |
| 2021 Q4 | -31.24 Billion KRW | -140.97% |
| 2021 Q3 | -12.96 Billion KRW | -47.4% |
| 2021 Q2 | -8.79 Billion KRW | -65.76% |
| 2021 FY | -58.51 Billion KRW | -218.3% |
| 2020 Q3 | -9.15 Billion KRW | -215.53% |
| 2020 Q1 | -2.49 Billion KRW | 17.45% |
| 2020 FY | -18.38 Billion KRW | -69.08% |
| 2020 Q2 | -2.9 Billion KRW | -16.45% |
| 2020 Q4 | -3.97 Billion KRW | 56.6% |
| 2019 FY | -10.87 Billion KRW | -146.89% |
| 2019 Q3 | -2.49 Billion KRW | 0.0% |
| 2019 Q4 | -3.01 Billion KRW | -21.02% |
| 2018 FY | -4.4 Billion KRW | -36.13% |
| 2017 FY | -3.23 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ORIENT BIO Inc. | 1.45 Billion KRW | 4421.483% |
| Green Cross Holdings Corporation | -16.43 Billion KRW | -281.94% |
| Green Cross Holdings Corporation | 34.43 Billion KRW | 282.317% |
| Pharmicell Co., Ltd. | 950.99 Million KRW | 6701.805% |
| Green Cross Corporation | 34.43 Billion KRW | 282.317% |
| GeneOne Life Science, Inc. | -48.36 Billion KRW | -29.803% |
| Celltrion, Inc. | 651.43 Billion KRW | 109.638% |
| Samsung Biologics Co.,Ltd. | 1155.98 Billion KRW | 105.431% |
| SK bioscience Co.,Ltd. | -4.73 Billion KRW | -1227.058% |
| SK Biopharmaceuticals Co., Ltd. | -37.52 Billion KRW | -67.322% |